4-(Phenylmethyl)-1-piperazineacetic acid 2-[[2-hydroxy-3-(2-propen-1-yl)phenyl]methylene]hydrazide
PAC-1
CAS: 315183-21-2
Molecular Formula: C23H28N4O2
4-(Phenylmethyl)-1-piperazineacetic acid 2-[[2-hydroxy-3-(2-propen-1-yl)phenyl]methylene]hydrazide - Names and Identifiers
4-(Phenylmethyl)-1-piperazineacetic acid 2-[[2-hydroxy-3-(2-propen-1-yl)phenyl]methylene]hydrazide - Physico-chemical Properties
| Molecular Formula | C23H28N4O2 |
| Molar Mass | 392.49 |
| Density | 1.14 |
| Solubility | DMSO: ≥10mg/mL |
| Appearance | solid |
| Color | white |
| pKa | 8.82±0.40(Predicted) |
| Storage Condition | Store at +4°C |
| Stability | Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol must be stored under inert gas at -80°C and will be stable for up to 2 months. |
| MDL | MFCD03302441 |
| Use | PAC-1 is an effective procaspase-3 (zymogen -3) activator with EC50 of 0.22 μM and is the first known small molecule that directly activates zymogen e-3 to caspase-3. |
| In vitro study | PAC-1 activated procaspase-3, producing caspase-3 with an EC50 of 0.22 μm, and procaspase-7 activated with an EC50 of 4.5 μm. Increased caspase 3 levels in cancer cell lines induced PAC-1 to selectively induce apoptosis, with IC50 values ranging from 0.35 μm for procaspase-3 cells to -3.5 μm for NCI-H226 cells in a manner proportional to the UACC-62 concentration. PAC-1 acts on primary cancer cells and induces apoptosis with IC50 of 3 nM to 1.41 μm, and more effectively acts on adjacent non-cancer cells with IC50 of 5.02 μm to 9.98 μm, directly related to the different procaspase-3 concentrations. PAC-1 activates procaspase-3 by sequestering zinc ions, thus alleviating zinc-mediated inhibition, and procaspase-3 activation itself becomes caspase-3. PAC-1 acts on Bax/Bak double knockout cells and, Bcl-2 and Bcl-xL-overexpressing cells to induce cell death. PAC-1 induces cytochrome c release in a caspase-3 independent manner and subsequently triggers downstream caspase-3 activation and cell death. PAC-1 acts on Apaf-1 gene knockout cells, does not induce apoptosis and caspase-3 activation, indicating that the formation of apoptotic bodies through PAC-1 mediated cell death is essential for the activation of caspase-3. |
| In vivo study | PAC-1 stable release of 5 mg low dose treatment of mice, significantly inhibited the growth of ACHN renal transplantation tumor. Oral treatment at a dose of 50 or 100 mg/kg in PAC-1 significantly inhibited the growth of lung cancer xenografts in NCI-H226 in a dose-dependent manner and significantly prevented the infiltration of cancer cells into lung tissue. PAC-1 the in vivo antitumor effect was attributed to activation of procaspase-3 and subsequent induction of apoptosis, consistent with in vitro activity. |
4-(Phenylmethyl)-1-piperazineacetic acid 2-[[2-hydroxy-3-(2-propen-1-yl)phenyl]methylene]hydrazide - Risk and Safety
| Risk Codes | R22 - Harmful if swallowed R36/37/38 - Irritating to eyes, respiratory system and skin. R50/53 - Very toxic to aquatic organisms, may cause long-term adverse effects in the aquatic environment. |
| Safety Description | S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S36/37 - Wear suitable protective clothing and gloves. S60 - This material and its container must be disposed of as hazardous waste. S61 - Avoid release to the environment. Refer to special instructions / safety data sheets. |
| UN IDs | UN 3077 |
| WGK Germany | 3 |
| HS Code | 29335990 |
4-(Phenylmethyl)-1-piperazineacetic acid 2-[[2-hydroxy-3-(2-propen-1-yl)phenyl]methylene]hydrazide - Preparation solution concentration reference
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 2.548 ml | 12.739 ml | 25.478 ml |
| 5 mM | 0.51 ml | 2.548 ml | 5.096 ml |
| 10 mM | 0.255 ml | 1.274 ml | 2.548 ml |
| 5 mM | 0.051 ml | 0.255 ml | 0.51 ml |
Last Update：2024-01-02 23:10:35
4-(Phenylmethyl)-1-piperazineacetic acid 2-[[2-hydroxy-3-(2-propen-1-yl)phenyl]methylene]hydrazide - Reference Information
| biological activity | PAC-1 is an effective procaspase-3 (zymogen -3) activator, EC50 is 0.22 μM, is the first known small molecule that directly activates zymogen e-3 to caspase-3. |
| target | TargetValue Procaspase-3 0.22 μM(EC50) |
| Target | Value |
| Procaspase-3 | 0.22 μM(EC50) |
| in vitro study | PAC-1 activation procaspase-3 to produce caspase-3,EC50 is 0.22 μM, and activation procaspase-7,EC50 is 4.5 μM. The increased caspase 3 level in the cancer cell line allows the PAC-1 to selectively induce apoptosis. In a proportional manner to the procaspase-3 concentration, IC50 is 0.35 μM acting on NCI-H226 cells to ~ 3.5 μM acting on UACC-62 cells. PAC-1 acts on primary cancer cells and induces apoptosis. IC50 is 3 nM to 1.41 μM, which is more effective in neighboring non-cancer cells. IC50 is 5.02 μM to 9.98 μM, which is directly related to different procaspase-3 concentrations. PAC-1 activate the procaspase-3 by chelating zinc ions, thus alleviating zinc-mediated inhibition and making procaspase-3 activation itself caspase-3. PAC-1 acts on Bax/Bak double gene knockout cells and, Bcl-2 and Bcl-xL-overexpressing cells to induce cell death. PAC-1 induce cytochrome c release in a caspase-3-independent manner, and subsequently trigger downstream caspase-3 activation and cell death. PAC-1 acting on Apaf-1 gene knockout cells will not induce apoptosis and caspase-3 activation, which indicates that the formation of apoptotic bodies through PAC-1-mediated cell death is essential for activating caspase-3. |
| in vivo study | PAC-1 treated mice at a low dose of 5 mg of stable release significantly inhibited the growth of ACHN renal transplant tumor. PAC-1 oral treatment at a dose of 50 or 100 mg/kg significantly hinders the growth of NCI-H226 lung cancer xenografts. This effect is dose-dependent and significantly prevents cancer cells from infiltrating lung tissue. PAC-1 in vivo antitumor effect was attributed to activation of procaspase-3 and subsequent induction of apoptosis, consistent with in vitro activity. |
| use | PAC-1 is a caspase 3 activator. Caspase activation is a key strategy in cancer therapy. Caspase 3 is a key executioner caspase and direct effector of apoptosis. Hallmark of many cancers is the circumv entin of signal in the activation of executioner caspases and loss of apoptotic response. EC50 for caspase 3 activation = 0.33 μ m and caspase 7=4.5 μM. The IC50 for apoptosis induction = 0.92 μM. El used caspase 3 level in cancerous cell lines and tissues allows PAC-1 to selectively inuce apoptosis in tissues. |
Last Update：2024-04-09 20:52:54
![4-(Phenylmethyl)-1-piperazineacetic acid 2-[[2-hydroxy-3-(2-propen-1-yl)phenyl]methylene]hydrazide](http://res.chembk.com/assets/images/structure/305823.gif)
Supplier List
Product Name: PAC-1 Visit Supplier Webpage Request for quotation
CAS: 315183-21-2
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
CAS: 315183-21-2
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Product Name: PAC-1 Visit Supplier Webpage Request for quotation
CAS: 315183-21-2
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
CAS: 315183-21-2
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History